A four-year financing deal was reached by CeloNova BioSciences with SWK Holdings and Congruent Investment Partners. The agreement is expected to provide CeloNova with capital for ongoing clinical trials, the release of its Cobra PzF NanoCoated coronary stent and other product initiatives.
CeloNova reaches financing deal with SWK, Congruent
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.